Published • loading... • Updated
Anvisa Prohibits Irregular Batches of Drug for Multiple Sclerosis
Summary by O Cafezinho
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Anvisa ordered to seize the lots H7953B14 and H7953B06 of Ocrevus (ocrelizumab), distributed in July 2026 by Laf Med, whose operating authorisation has been inactive since October 2025.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
